Results 151 to 160 of about 267,118 (262)

Blood Cell‐Camouflaged Liquid Metal Nanoconjugates Orchestrate Treg Depletion and STING‐Amplified Photothermal Immunity for Metastatic Triple‐Negative Breast Cancer Therapy

open access: yesAdvanced Science, EarlyView.
Whole‐blood biomimetic engineering transforms liquid metal nanoparticles into a tripartite immunotherapeutic platform that orchestrates regulatory T‐cell depletion, photothermal‐induced immunogenic cell death, and activation of the stimulator of interferon genes pathway.
Nina Sang, Eijiro Miyako
wiley   +1 more source

Management of thrombosis in patients with hematologic malignancies

open access: yes, 2002
The management of thrombosis in patients with cancer is a clinical challenge. Although the prevalence of thromboembolic complications in hematologic malignancies is lower than that reported for solid tumors, thrombotic events are increasingly being ...
Vianello F., Prandoni P., Piccioli A.
core  

IFI27 and BAX are Essential for GSDME‐Mediated Myeloma Cell Pyroptosis

open access: yesAdvanced Science, EarlyView.
The proposed model of GSDME‐mediated MM cell pyroptosis modulated by IFI27 and BAX. IFI27 is downregulated in MM cells. Upon pyroptotic stimulation, such as DOX or ETO treatment, IFI27 is induced, therefore liberating BAX from BCL‐2 ❶. BAX is then recruited to mitochondria and forms homo‐oligomeric channels in OMM, therefore leading to cytochrome C ...
Yaoli Cui   +12 more
wiley   +1 more source

Endothelial Injury as a Potential Contributor to Cardiovascular Toxicity in Hematologic Malignancies. [PDF]

open access: yesDiseases
Altić A   +9 more
europepmc   +1 more source

Carrier‐Free Berberine/Nitidine Chloride Self‐Assembled Nanoparticles Induce Ferroptosis to Overcome Bortezomib Resistance in Multiple Myeloma

open access: yesAdvanced Science, EarlyView.
A schematic illustrating the fabrication process and ferroptosis‐mediated therapeutic mechanism of carrier‐free self‐assembled BBR/NC‐SAPs for overcoming bortezomib resistance in multiple myeloma. ABSTRACT Therapeutic relapse driven by bortezomib resistance represents a formidable clinical barrier in the management of multiple myeloma (MM).
Yiwen Lv   +16 more
wiley   +1 more source

Exercise and nutrition in hematologic malignancies: translational evidence and emerging interventions. [PDF]

open access: yesBlood Neoplasia
Loh KP   +8 more
europepmc   +1 more source

A Drug‐Gated, Modular STAb‐T Immunotherapy With External Control

open access: yesAdvanced Science, EarlyView.
Engineered STAb‐TON cells act as programmable living factories that continuously secrete inactive antibody modules, which assemble extracellularly into a functional T cell engager only upon small‐molecule administration. This externally controlled platform enables reversible, on‐demand regulation of antitumor immunity, establishing a new paradigm for ...
Susana Luengo‐Arias   +23 more
wiley   +1 more source

An Intravesical Akkermansia muciniphila‐Based Chemo‐Immunotherapeutic Platform for Bladder Cancer

open access: yesAdvanced Science, EarlyView.
Pasteurized Akkermansia muciniphila is engineered into an intravesical F127/doxorubicin platform that couples localized chemotherapy with immune remodeling. By inducing apoptosis, ferroptosis, and immunogenic cell death, this chemo‐immunotherapeutic system enhances dendritic‐cell maturation, antigen cross‐presentation, and tumor‐specific CD8+ T‐cell ...
Rongkang Li   +11 more
wiley   +1 more source

Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
In the murine triple‐negative breast cancer (TNBC) model, chemotherapy effectively increases tumor neoantigen burden (TNB). Here, the study constructs a liposomal nanovaccine using antigens derived from in vitro chemotherapy‐treated paclitaxel‐resistant TNBC 4T1 cells.
Bo Chen   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy